The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Ralph V. Boccia
Honoraria - Amgen; AstraZeneca; Blueprint Medicines; BMS; DSI; Genentech; Incyte; Janssen; Rigel
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; DSI; Genentech; Incyte; Janssen; Rigel
Speakers' Bureau - Amgen; AstraZeneca; DSI; Genentech; Incyte; Janssen; Rigel
Research Funding - Amgen (Inst); AstraZeneca (Inst); DSI (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Rigel (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; DSI; Genentech; Incyte; Janssen; Rigel
 
John H Strickler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Pionyr; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Takeda; Viatris; Zentalis
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Travel, Accommodations, Expenses - Guardant Health; Seagen
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Lilly; Merck Serono; MSD; Pfizer; Roche; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche
 
Cynthia A. Sirard
Employment - Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics
 
Erin K Walsh
Employment - Leap Therapeutics; ZIOPHARM Oncology
Stock and Other Ownership Interests - Leap Therapeutics
Travel, Accommodations, Expenses - Leap Therapeutics; ZIOPHARM Oncology
 
Elizabeth C Parker
Employment - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Travel, Accommodations, Expenses - Leap Therapeutics
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)